Kazia Therapeutics Ltd. (KZIA) announced on Wednesday the findings from a Phase I study that explored the efficacy of combining Paxalisib and radiation therapy to treat patients suffering from solid tumor brain metastases or leptomeningeal metastases associated with PI3K pathway mutations.
The results showed that more than two-thirds of the participants achieved intracranial response at the maximum tolerated dose, with a 67 percent partial response rate observed in those treated with 45 mg of Paxalisib and radiotherapy.
Kazia reported that the treatment was well-tolerated at the maximum dose of 45 mg per day in patients with advanced solid tumors, brain metastases, and PI3K pathway mutations.
Commenting on the data, John Friend, CEO of Kazia, noted that the combination therapy appears to be a promising approach to tackling tumor radioresistance in patients with PI3K pathway mutations.
As of now, Kazia's stock has risen by 11.37 percent, reaching $0.48 on the Nasdaq.
